News from us and our partners

Tags

Topics

0 results

News
15 November, 2017
Inotrem granted access to priority medicines scheme (PRIME) for its lead compound MOTREM™ in the treatment of septic shock.
News
15 November, 2017
Inotrem obtient le statut de médicament prioritaire (PRIME) pour sa molécule leader MOTREM™ dédiée au traitement du choc septique.
News
13 November, 2017
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
News
10 November, 2017
Inotrem et Roche Diagnostics signent un accord de collaboration R&D pour développer un test diagnostic dans le domaine du choc septique.
News
10 November, 2017
Inotrem and Roche Diagnostics sign a R&D collaboration agreement in the field of septic shock to develop a companion diagnostic test
News
31 October, 2017
Highlife lève 12.3M€ lors d'un tour de financement mené par Sofinnova Partners
News
31 October, 2017
Highlife closes €12.3 million financing round led by Sofinnova Partners
News
20 October, 2017
Avantium nominates Kees Verhaar as supervisory board chair
News
19 October, 2017
Pixium Vision receives approval for First-in-Human Clinical Trial of PRIMA, its miniaturized sub-retinal implant
News
18 October, 2017
Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors
News
11 October, 2017
Shockwave Medical Announces $35 Million in New Financing
News
9 October, 2017
la Relève" Les Echos
News
3 October, 2017
Noxxon publie des données précliniques de preuve de concept relatives à l'association du composé phare NOX-A12 à des inhibiteurs de point de contrôle
News
30 September, 2017
Nucana plc announces pricing of initial public offering
News
29 September, 2017
Noxxon provides update ongoing phase 1/2 clinical trial with lead program NOX-A12
News
27 September, 2017
Henrijette Richter appointed Managing Partner of Sofinnova Partners

Inotrem granted access to priority medicines scheme (PRIME) for its lead compound MOTREM™ in the treatment of septic shock.

Inotrem obtient le statut de médicament prioritaire (PRIME) pour sa molécule leader MOTREM™ dédiée au traitement du choc septique.

ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

Inotrem et Roche Diagnostics signent un accord de collaboration R&D pour développer un test diagnostic dans le domaine du choc septique.

Inotrem and Roche Diagnostics sign a R&D collaboration agreement in the field of septic shock to develop a companion diagnostic test

Highlife lève 12.3M€ lors d'un tour de financement mené par Sofinnova Partners

Highlife closes €12.3 million financing round led by Sofinnova Partners

Avantium nominates Kees Verhaar as supervisory board chair

Pixium Vision receives approval for First-in-Human Clinical Trial of PRIMA, its miniaturized sub-retinal implant

Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors

Shockwave Medical Announces $35 Million in New Financing

la Relève" Les Echos

Noxxon publie des données précliniques de preuve de concept relatives à l'association du composé phare NOX-A12 à des inhibiteurs de point de contrôle

Nucana plc announces pricing of initial public offering

Noxxon provides update ongoing phase 1/2 clinical trial with lead program NOX-A12

Henrijette Richter appointed Managing Partner of Sofinnova Partners